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Abbreviation list (abbreviations used more than once, in alphabetical order): 
 
ARNT - aryl hydrocarbon nuclear translocator 
 BCRP - breast cancer resistant protein 
  CAD - C-terminal activation domain 
  CAIX - carbonic anhydrase IX 
  CAV1 - caveolin-1 
    ccRCC - clear cell renal cell carcinoma 
  CSC - cancer stem cells 
   DAG - diacylglycerol 
   DUSP2 - dual specificity phosphatase 2 
  EGF(R) - epidermal growth factor (receptor) 
 EMT - epithelial-mesenchymal transition 
  FGF(R) - fibroblast growth factor (receptor) 
 GAS6 - growth arrest-specific 6 
  GDNF - glial-derived neurotrophic factor 
  GTP - guanosine triphosphatase 
  GTPases - guanosine triphosphatases 
  HCC - hepatocellular carcinoma 
  HGF - hepatocyte growth factor 
  HIF - hypoxia inducible factor 
   HNSCC - head and neck squamous cell carcinoma 
 HUVECs - human umbilical vein endothelial cells 
 IGF(R) - insulin-like growth factor (receptor) 
 IR - insulin receptor 
    IRES - ribosome entry sites 
   IRS - insulin receptor substrates 
  MAPK - mitogen-activated protein kinase 
 miRNA - microRNAs 
   MSP - macrophage stimulating protein 
  mTOR – mammalian target of rapamycin 
   Necl-2 - Nectin-like molecule-2 
  NF-kB - nuclear factor-kB 
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NRG-1 - Neuregulin-1 
   NSCLC - non-small cell lung cancer 
  PDGF(R) - platelet derived growth factor (receptor) 
PHD - prolyl hydroxylase 
   PI3K - phosphatidylinositol 3-kinase 
  PKA - protein kinase A 
PKC – protein kinase C 
   PLCγ - phospholipase Cγ 
   PP2A - protein phosphatase-2A 
  RACK1 - receptor for activated protein kinase C 
 RCC - renal cell carcinoma 
   RON - recepteur d'origine nantais 
  ROS - reactive oxygen species 
   RTK - receptors tyrosine kinase 
  TGFα - tumor growth factor α 
   Top - Topoisomerase 
   uPA - urokinase-like plasminogen activator 
 UTR - untranslated region 
   VEGF(R) - vascular endothelial growth factor (receptor) 
VHL - Von Hippel-Lindau 
   VSMS - vascular smooth muscle cells 
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Abstract 
Deregulated signaling via receptor tyrosine kinase (RTK) pathways is prevalent in numerous 
types of human cancers and is commonly correlated with worst prognosis, resistance to 
various treatment modalities and increased mortality. Likewise, hypoxic tumors are often 
manifested by aggressive mode of growth and progression following an adaptive genetic 
reprograming with consequent transcriptional activation of genes encoding proteins, which 
support tumor survival under low oxygen-related conditions. Consequently, both the HIF 
system, which is the major mediator of hypoxia-related signaling, and numerous RTK 
systems are considered critical molecular targets in current cancer therapy. It is now evident 
that there is an intricate molecular crosstalk between RTKs and hypoxia-related signaling in 
the sense that hypoxia can activate expression of particular RTKs and/or their corresponding 
ligands, while some RTK systems have been shown to trigger activation of the HIF 
machinery. Moreover, signaling regulation of some RTK systems under hypoxic conditions 
has also been documented to take place in a HIF-independent manner. With this review we 
aim at overviewing the most current observations on that topic and highlight the importance 
of the potential co-drugging the HIF system along with particular relevant RTKs for better 
tumor growth control. 
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1. Introduction  
Receptor tyrosine kinases (RTKs) are cell surface proteins responsible for a tight 
regulation of a broad spectrum of downstream intra-cellular processes [1]. All RTKs are 
similarly structured, with a ligand binding region in the extracellular domain, a single 
transmembrane helix and a cytoplasmic region that comprises the protein tyrosine kinase 
domain as well as additional carboxy-terminal and juxtamembrane regulatory regions [2]. 
Following growth factor binding, the extracellular region undergoes self-association, guiding 
the intracellular domains into a dimeric conformation, which activates their tyrosine kinase 
enzymatic activity. One or more tyrosines in one receptor within the dimer are trans-
phosphorylated by a neighboring RTK. The phosphorylated receptor subsequently recruits 
intracellular adaptor and transducing effectors, leading to cascades of signaling events that 
control growth, proliferation, differentiation and migration [1-3]. 
 Aberrant activity of RTKs is a hallmark of a wide range of human cancers and 
frequently correlates with poor prognosis [4, 5]. In normal cells, activation of RTKs and 
downstream signaling pathways is reversible and tightly regulated, whereas in cancer cells, 
RTKs acquire transforming functions due to activating mutations, gene amplification-
dependent or -independent overexpression and aberrant autocrine/paracrine loops [6]. Many 
cancers of different histotypes often harbor genetic alterations in either RTKs themselves or in 
transducing elements of their downstream pathways, resulting in deregulated signaling output 
[7, 8]. Consequently, numerous RTK systems represent attractive therapeutic targets [9] with 
two leading approaches that have been translated into clinically-relevant modes to inhibit their 
corresponding signaling: monoclonal antibodies against the receptor itself or the putative 
ligand and small-molecule inhibitors that block the receptor catalytic activity [10]. Although 
the proof of principle of RTK targeted therapy has been well documented, acquired resistance 
to anti-RTKs agents ultimately develops [11]. Drug resistance usually arises through point 
mutations within the kinase domain, gene amplification or overexpression, or through 
activation of downstream bypass signaling pathways [12]. 
 Another fundamental biologic feature, which is largely involved in aggressive 
manifestations of tumor growth and progression, is hypoxia. Solid tumors often become 
hypoxic when new blood vessels associated with tumor growth develop irregularly, resulting 
in poor blood flow and subsequent inefficient delivery of oxygen [13]. Poor oxygenation 
induces a series of cellular physiologic adaptations that are largely mediated via the hypoxia-
inducible factors α (HIF-α’s) transcription system that sustains and fosters tumor survival [14, 
15]. Mammalian HIF-α subunits are encoded by three distinct genes: HIF-1α, HIF-2α, and 
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HIF-3α. HIF-1α is the most ubiquitously expressed, whereas HIF-2α and HIF-3α exhibit a 
more restricted tissue distribution [16]. Under normoxic conditions, oxygen-dependent prolyl-
hydroxylases covalently modify the hypoxic response subunit HIF-1α, converting it to a 
hydroxylated form, which subsequently undergoes ubiquitination by the von Hippel-Lindau 
(VHL) E3 ubiquitin ligase and eventual proteasome-dependent degradation [[13]. In the 
presence of low oxygen concentrations, prolyl-hydroxylases are inhibited, preventing HIF-1α 
from being degraded. Hence, HIF-1α accumulates in the nucleus, where it associates to the 
constitutively expressed HIF-1β subunit (also known as the aryl hydrocarbon nuclear 
translocator (ARNT)). This complex activates gene transcription by binding to specific HIF-
responsive elements of target genes, which are activated under hypoxic conditions [17]. 
Under normal physiologic conditions, as during embryogenesis, hypoxia favors the generation 
of niches that preserve optimal conditions for the maintenance of pluripotent cells [17]. Low 
oxygen tension contributes to both physiologic stemness and invasive growth, traits, which 
when aberrantly develop in tumor cells, lead to an aggressive malignant phenotype [17].  
As to signaling interplays between hypoxia and RTKs pathways, the activation of 
vascular endothelial growth factor receptor (VEGFR) via HIF-mediated VEGF transcriptional 
activation and consequent accelerated tumor angiogenesis and systemic dissemination, 
represents one of the first described examples in that respect [18]. In this review, we aim at 
discussing the far broader emerging molecular crosstalk between RTKs activity and tumor 
hypoxia, which are important to understand the complex mechanisms that confer aggressive 
manifestation of hypoxic tumors. 
 
 
2. Hypoxia-induced regulation of RTK signaling 
 
Numerous genes, including those encoding for RTKs and their ligands and whose expression 
is regulated under hypoxic conditions, either directly by HIF-1α and HIF-2α transcriptional 
activation or by distinct hypoxia-driven mechanisms, have been identified and described 
using expression profiling studies [19-22]. In this chapter, we will focus on RTK systems that 
are transcriptionally activated by HIF-1α and HIF-2α and we will also describe HIF-1α- and 
HIF-2α-independent mechanisms that were shown to stimulate RTKs signaling under hypoxic 
conditions (Figure 1). 
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2.1. Induction of RTK ligands 
 
Low oxygen tension has been associated with elevated production of several RTK ligands. In 
that respect, expression of vascular endothelial growth factor-A (VEGF-A) was shown to be 
induced by hypoxia in most cell types [13, 23], both in vitro and in vivo [24]. The VEGF 
family consists of the four homodimeric members VEGF-A, VEGF-B, VEGF-C and VEGF-D 
that bind and activate three corresponding VEGF receptors (VEGFR-1, VEGFR-2 and 
VEGFR-3), which are expressed by endothelial cells and many tumor types [25, 26]. Under 
hypoxic conditions, tumor cells secrete enhanced levels of VEGF family members in a 
paracrine fashion to stimulate proliferation and migration of endothelial cells, thereby 
promoting tumor-associated angiogenesis. Additionally, VEGFs can also act in an autocrine 
manner as survival factors for tumor cells themselves [23, 27]. HIF-1α was identified for the 
first time to be involved in the transcriptional activation of VEGF-A in hypoxic hepatoma 
cells [18]. Transcriptional response of a reporter gene expression was shown to be mediated 
via VEGF 5’-flanking sequences, which contain a functional HIF-1α binding site [18]. Later, 
it was discovered that the VEGF-D promoter region also contains sequences responsible for 
VEGF-D induction in vascular smooth muscle cells [28]. In addition to HIF-1α-mediated 
direct transcriptional activation of VEGF, hypoxia has been shown to promote VEGF 
production by additional mechanisms. In retinal microvascular cells, it was reported that 
hypoxia-induced adenosine release, resulting from decreased recycling by adenosine kinase, 
stimulates adenosine A2 receptor and activates the cAMP-dependent protein kinase A (PKA) 
pathway, thereby increasing VEGF mRNA and protein levels [29, 30]. Moreover, hypoxia 
was shown to increase kinase activity of SRC in glioma cells, which in turn induces VEGF 
expression [31]. Several studies reported that in addition to increased transcriptional 
activation, VEGF mRNA stability is enhanced under hypoxia [32-34]. The increased stability 
was suggested to be mediated by a hypoxia-induced complex which binds to sequences in the 
3’UTR of the VEGF mRNA [32]. These mechanisms, independent of HIF-1α-induced 
transcription, play an important role in VEGF induction. In fact, even though the VEGF-C 
gene has not been found to harbor HIF-binding sites, hypoxia-associated VEGF-C production 
has been demonstrated in breast and lung carcinomas in vitro [23]. 
Increased production of VEGFs is also known to be induced by deregulated production of 
PDGF [25, 35]. This second mechanism is indirectly mediated by the HIF system, too. In 
breast cancer cells, it was specifically shown that HIF-1α binds to a site in intron 3 of the 
PDGF-B gene to activate its transcription [36]. The PDGF family consists of disulfide-bonded 
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homodimers of A-, B-, C- and D-polypeptide chains as well as the heterodimer PDGF-AB. 
Binding of the PDGF isoforms to α- and β- tyrosine kinase receptors (PDGFRα and PDGFRβ) 
promotes new vessel formation [36]. Several studies reported correlations between HIF-1α 
expression and PDGF-B in breast cancer [36] and glioma [37]. In mice bearing triple negative 
breast cancer orthografts, lymphangiogenesis and lymphatic metastasis were shown to be 
blocked by treatment with the cardiac glycoside digoxin [38], which inhibits HIF-1α, or by 
the tyrosine kinase inhibitor imatinib via PDGFRβ targeting. This suggests that breast cancer 
patients might benefit from treatment aiming at targeting either HIF-1α or PDGFRβ alone or 
both together [36]. 
Another RTK ligand playing an important role in hypoxia-induced tumorigenesis is insulin-
like growth factor 2 (IGF2), which exerts its biologic activity via binding to the insulin-like 
growth factor 1 receptor (IGF1R) tyrosine kinase [39]. Activation of IGF1R in tumors is very 
rarely caused by gene amplification or point mutations. Constitutive receptor activation is 
usually a consequence of increased ligand availability [40]. IGF1R is activated upon binding 
of IGF1 or IGF2. IGF2 is the most highly up-regulated gene in colon cancers [41], which in 
turn show the highest frequency of HIF1α overexpression. Expression of IGF2 was shown to 
be induced by hypoxia in HEPG2 hepatocellular carcinoma (HCC) cells [42]. Although IGF2 
lacks a defined hypoxia responsive element containing a HIF-1 binding site, it is still possible 
that HIF1α has an indirect effect on IGF2 expression [43]. 
Overexpression of HIF1α/HIF-2α can also occur under non-hypoxic conditions. In that 
respect the majority of ccRCC, the most common subtype of renal cell cancer (RCC), bear bi-
allelic-inactivating mutations of the VHL tumor suppressor gene [44]. As a consequence, 
VHL
-/-
 ccRCC cells have a constitutive, oxygen-independent activation of HIF1α/HIF-2α 
[45]. Unregulated growth of these cells was reported to be promoted by activating the 
transforming growth factor-α (TGF-α)/EGFR pathway. It was shown that overproduction of 
TGF-α by VHL-/- ccRCC is a direct consequence of HIF activation [45]. Notably, the use of 
EGFR inhibitors was as efficient as reintroducing VHL for abolishing the ability of ccRCC 
cells to form tumors in nude mice [46-48]. 
 
2.2.HIF-related transcriptional activation of RTKs: MET, AXL and RON 
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MET is the high-affinity receptor for hepatocyte growth factor (HGF) strongly implicated in 
physiological as well as in pathological cell growth, proliferation, migration and is the master 
regulator of the embryonic ‘invasive growth’ morphogenetic program [17]. Notably, already 
more than 10 years ago, MET expression was shown to be directly induced under hypoxic 
environment both in vitro and in vivo experimental setups. It was shown that both MET 
protein and mRNA levels increase in a panel of cancer cell lines after their exposure to low 
oxygen tension [49]. In experimental tumors, the formation of a gradient of MET protein 
expression that is inversely proportional to blood vessel proximity was observed [49]. By 
analyzing the human MET promoter, this induction was demonstrated to be of transcriptional 
origin and mediated by two different HIF-1α binding sites and an AP-1 site, all located in the 
5’untranslated region (5’UTR) [49, 50].  
On one hand, increased expression of MET alone favors receptor oligomerization and 
subsequent ligand-independent activation, on the other hand, overexpression of the MET 
receptor was shown to render tumor cells more susceptible to stimulation by HGF [15, 49]. In 
several cancer cell lines, hypoxia and HGF were reported to synergize in inducing invasive 
growth [49]. One plausible explanation for these observations relies on the fact that the 
activity of proteases is promoted by hypoxia [51, 52]. HGF needs to be extracellularly 
converted from its inactive precursor form, pro-HGF, to mature HGF by urokinase-type 
plasminogen activator in order to bind to MET. Hence, elevated active HGF levels in hypoxic 
tumor environments might be a consequence of hypoxia-stimulated increase in protease 
activity [51-54]. By RNA interference, it was also demonstrated using a panel of cancer cell 
lines that increased invasiveness occurs due to higher levels of MET [49]. Increased motility 
and invasion triggered by MET activity represent the manifestation of activation of a cellular 
genetic reprograming for escaping hypoxic environment [15, 49]. 
 
Further insights over the correlation between hypoxia and MET signaling has been reported in 
2006 by Ide et al who reported over the impact of MET activation on cancer cells interaction 
with the surrounding tumor stroma [55]. In that respect, the invasiveness of PK8 pancreatic 
cancer cells incubated with hypoxic conditioned medium prepared from MRC5 fibroblast 
cells, was shown to increase under low oxygen tension. This effect was demonstrated to arise 
through increased MET expression in PK8 cells and HGF secretion from MRC5 cells leading 
to an elevation of MET phosphorylation. The removal of HGF from the conditioned medium 
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reduces the invasive activity of PK8 cells, showing the relevant impact of hypoxic stimulation 
on pancreatic cancer as well as stromal cells [55]. 
 
Recent reports originating from our lab suggest that MET is involved in DNA repair 
after exposure to ionizing radiation [56, 57]. The use of the selective small molecule MET 
inhibitor PHA665752 was shown to impair homologous recombination repair of DNA double 
strand breaks in gastric adenocarcinoma cell lines [58]. Aberrant MET expression in poorly 
oxygenated tumors could provide a possible explanation as why hypoxic tumors display 
resistance towards radiation therapy [13], providing a further rationale for MET targeting in 
hypoxic tumors. 
 
Using a variety of tumor cell line models, Lee et al. found a signaling convergence of 
HGF and hypoxia resulting in synergistic tumor cell invasiveness [59]. Suppression of the 
dual specificity phosphatase 2 (DUSP2) transcript and protein levels by hypoxia-induced 
reactive oxygen species (ROS) was shown to promote ERK activation resulting in cellular 
invasiveness. The portion of ERK activation under hypoxia is independent of MET abundance 
or signaling and thus additive to ERK activation induced by HGF [59]. On the other hand, 
hypoxia-induced ROS were reported to induce diacylglycerol (DAG) generation by 
phospholipase Cγ (PLCγ), leading to protein kinase C activation (PKC) and increased protein 
phosphatase-2A (PP2A) activity, thereby suppressing HGF-induced AKT activation [59]. 
Hypoxic AKT suppression was associated with a decrease in cell proliferation and induction 
of autophagy [59], playing an important role in enhancing cell viability in adverse conditions 
[60, 61]. These observations show the plasticity of invasive and proliferative tumor states, 
which can be mediated by the convergence of hypoxia and MET signaling pathways. 
 
In addition to the aforementioned, MET can be activated in various HGF-independent 
manners. In clear cell renal cell carcinomas (ccRCC) cell lines, signaling via the AXL RTK 
was reported to regulate lateral activation of MET through SRC. Binding of the growth arrest-
specific 6 (GAS6) ligand to AXL leads to the formation of a complex between AXL and SRC 
[62]. Through this event, SRC is activated and phosphorylates the intracellular domain of 
MET receptor to release its kinase domain from a state of autoinhibition [63]. This process is 
particularly increased under hypoxia since HIF-1α and HIF-2α have been demonstrated to 
bind to a functional HIF binding site in the AXL promoter, leading to increased expression of 
AXL in ccRCC cells [62]. 
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AXL has been described as an important mediator of tumor invasion and metastasis in a 
number of cancers [64]. Of therapeutic relevance, the invasive and metastatic phenotype of 
ccRCC cells in particular, has been reported to reverse by inactivation of the GAS6/AXL 
signalling axis using a soluble AXL decoy receptor [62]. According to analysis of primary 
prostate cancer lesions and bone metastases, AXL, GAS6 and HIF-1α have been found to be 
all co-expressed in these malignant lesions [62]. Under normoxic conditions, GAS6 promotes 
phosphorylation and ubiquitination of AXL via interaction with the ubiquitin ligase c-CBL, 
leading to downregulation of AXL protein. However, hypoxia was shown to interfere with 
GAS6-mediated negative regulation of AXL expression in prostate cancer cell lines [65]. 
Hence, in a hypoxic tumor microenvironment stabilization of AXL expression may underlie 
driving of metastasis progression [66]. The finding that both AXL and MET are direct targets 
of HIF-1α/HIF-2α reveals a potent mechanism of hypoxic tumors to sustain malignant 
phenotypes [62]. 
 
Finally, the other member of the MET RTK family, the macrophage-stimulating protein 
receptor/Recepteur d’Origine Nantais (RON), has been shown to cross-talk with MET [67] 
and in parallel, several human tumor tissues show increased RON expression [68]. 
Interestingly, in a panel of human breast cancer cell lines, RON was reported to be 
transcriptionally activated through HIF-1α binding to the RON promoter in which two HRE 
are located [69]. Additionally and following hypoxic stress, RON was suggested to 
translocate to the nucleus and to interact with HIF-1α in urothelial cancer cells, an interaction, 
which requires RON’s tyrosine kinase activity [70]. The RON-HIF-1α complex was shown to 
bind to the c-JUN promoter and synergistically activate the expression of the c-JUN gene, 
resulting in cell proliferation, survival and migration in vitro and tumorigenicity in vivo [70]. 
These observations suggest RON targeting as a potential therapeutic strategy to interfere with 
tumorigenic effects of nuclear RON under hypoxic conditions [70]. 
 
 
2.3. HIF-independent regulation of ErbB, IGFR and FGFR family members 
under hypoxia 
 
Independently of direct HIF-1α/HIF-2α-driven transcriptional activation, hypoxia exerts a 
strong impact on members of the ErbB family RTKs that consists of EGFR/ErbB1, HER2 
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/ErbB2, HER3/ErbB3 and HER4/ErbB4 [71] whose aberrant activation by EGF family of 
growth factors is strongly associated with tumorigenesis, invasion and metastasis [72] 
Deregulated activity of ErbB receptors due to gene amplification, overexpression or mutations 
in numerous types of human cancers is tightly associated with poor prognosis and resistance 
to various treatment modalities [73-75]. 
 
Tumor hypoxia and EGFR expression have been found to correlate in a series of resected non-
small cell lung cancer (NSCLC) tumors [76]. Hypoxia and HIF-2α activation were 
specifically shown to induce EGFR overexpression by increasing EGFR mRNA translation in 
NSCLC cancer cell lines [76]. Mechanistically, HIF-2α activation could either directly induce 
the expression of an activator of EGFR translation or inhibit a negative regulator of receptor 
synthesis. Following treatment with the EGFR inhibitors AG1478 [77] and PD153035 [78], 
an IC50 increase proportional to elevated EGFR levels was observed in HIF-2α-expressing 
cells. In order to clinically compensate constitutive receptor production, continuous 
administration of higher drug concentrations would be required [79]. Hence, EGFR up-
regulation may be circumvented by inhibition of HIF-2α using the topoisomerase II inhibitor 
etoposide [79, 80]. 
 
In addition, EGFR activity is affected by hypoxia through another mechanism, which involves 
also HER4. Hypoxia-induced activation of HIF-1α and HIF-2α was reported to prolong EGFR 
[81] and HER4 [82] signaling in ccRCC and mammary carcinoma, respectively. Using cell 
line models, it was demonstrated that this effect arises through a delaying endocytosis-
mediated deactivation of the receptors [81, 83]. Endocytosis consists of a sequence of early 
and late endosomal fusion events mediated by RAB proteins, a group of RAS-like small 
guanosine triphosphatases (GTPases) [84], which lead to degradation of internalized receptors 
in lysosomes. The best studied mediator of early endosome fusion is RAB5 [85]. ccRCC 
tumors with strong hypoxic signatures were shown to have reduced expression of rabaptin-5, 
a critical effector of RAB5. Consistent with this finding, rababtin-5 mRNA and protein levels 
were reported to inversely correlate with HIF status in renal oncocytomas and breast cancer 
specimens [81]. 
 
Apart of this mechanism, Wang et al. showed caveolin-1 (CAV1) to promote ligand-
independent activation of EGFR in hypoxic ccRCC cells [86]. CAV1 is a major structural 
component of caveolae, which are specialized lipid raft microdomains on the cell membrane 
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[87]. CAV1 is a direct transcriptional target of HIF-1α and HIF-2α and its elevated expression 
has been associated with larger tumor size, grade and stage as well as resistance to 
conventional therapies and poor prognosis. Under hypoxia, the formation of caveolae 
increases and some fraction of EGFR in the fluid of cell membrane milieu localizes there. The 
substantially smaller surface area of caveolae relative to the plasma membrane permits ligand-
independent activation of EGFR [86]. This mechanism bypasses the requirement for ligand 
engagement to initiate receptor activation when ligand availability may be limited [86]. 
 
In non-transformed cells, signaling by ErbB family receptors is tightly regulated through 
specific endogenous mechanisms. HER2-catalyzed tyrosine phosphorylation of HER3 was 
shown to be inhibited by the immunoglobuline-like cell adhesion molecule Nectin-like 
molecule-2 (Necl-2) [88]. This protein plays important roles in a variety of cellular functions 
and regulates a wide range of events from normal development to tumorigenesis [72]. 
Through its mediated inhibition of HER2/HER3 signaling, Necl-2 serves as a tumor 
suppressor in many types of cancers [89]. In colon cancer cells, Necl-2 protein levels were 
found to decline under hypoxic conditions. Consistent with this finding, hypoxia was shown 
to increase HER2/HER3 signaling in these cells [72]. Hypoxia down-regulates Necl-2 in a 
manner that is independent of mRNA transcription and HIF-1α. Although enhanced 
expression of many hypoxia induced proteins is mediated by HIF-1α or alternatively by 
nuclear factor-κB (NF- κB) [90, 91], it is not well characterized yet by which factor or protein 
complex hypoxia-induced reduction of Necl-2 is mediated [72]. 
 
To date, discovery and development of therapies targeting ErbB receptors have improved 
treatment outcome for many cancer patients. However, due to the development of resistance 
mechanisms to these drugs, current treatment strategies experience challenging limitations 
[71]. Following treatment of NSCLC cells that harbor activating EGFR mutations (exon 19 
deletion and L858R) by a selective EGFR inhibitor gefitinib, a small fraction of cells that 
express stem cell markers are reported to survive [92]. Cancer stem cells (CSCs) are 
maintained in a quiescent state, which is considered to render them more refractory to 
anticancer drugs, potentially enabling tumor relapse [93, 94]. Hypoxic microenvironment was 
reported to be an important stem cell niche that favours CSCs survival [92, 95]. For example, 
hypoxia was shown to increase the population of gefitinib-resistant CSCs by activation of 
IGF1R [92]. Dallas et al suggested that IGF1R plays a critical role in the persistence of CSCs, 
as expression of the stem cell markers CD133 and CD44 is linked to increased 
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phosphorylated and total IGF1R in chemoresistant colon cancer cells [96]. Hypoxia-induced 
activation of IGF1R might be mediated by HIF-1α as the use of the nitric oxide-guanylate 
cyclase activator YC-1 [97], which downregulates HIF-1α, was shown to suppress receptor 
signaling. Targeting IGF1R signaling has been suggested to be a promising strategy for 
overcoming therapy resistance in tumors with activating EGFR mutatios induced by CSCs 
and hypoxia [92]. 
 
With respect to aspects related to regulation of gene expression, hypoxia has been shown to 
modulate expression of various microRNAs (miRNAs) [98]. miRNAs are small, single 
stranded RNA molecules that bind target mRNAs resulting in suppression of protein 
translation and/or cleavage of the corresponding mRNA [99, 100]. In normal human 
urothelial cell lines, miR-100 was shown to target fibroblast growth factor receptor 3 
(FGFR3) and in malignant urothelial patient samples, expression of miR-100 was observed to 
negatively correlate with FGFR3 mRNA [101]. FGFR3 is one of four members of the FGFR 
family of RTKs that functions as cell surface receptor for FGF1, FGF2, FGF4, FGF9 and 
FGF18 [102]. By employing RT4, RT112 and T24 bladder cancer cell lines, Blick et al have 
reported that miR-100 expression is suppressed under hypoxic conditions [98] and in turn, 
hypoxia was shown to increase FGFR3 mRNA levels [98]. Additionally, and according to 
analysis of a breast cancer patient cohort by Buffa et al in 2011, expression of miR-100 
negatively correlates with tumor hypoxia [103]. These findings suggest that hypoxia-related 
miR-100 levels decrease may represent a general mechanism, which may apply for different 
tumor types. HIF-1α seems also to play a role in the described negative regulation of this 
particular tumor suppressor miRNA as its knockdown suppresses FGFR3 levels in hypoxic 
conditions. However, the detailed molecular mechanisms have yet to be defined, as no HIF-
1α-binding sites have been found in the FGFR3 promoter and hypoxic suppression of miR-
100 is not necessarily reversed by HIF-1α knockdown [98]. 
 
 
3. Induction of the HIF pathway through RTK signaling 
 
This section focuses on observations demonstrating activation of the HIF pathway by various 
mechanisms, which are triggered via signaling by RTK systems (summarized in Figure 2). 
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3.1. ErbB family receptors 
 
Signaling by EGFR has been shown to increase the level of HIF-1α in a variety of cancer cell 
types, including prostate cancer, head and neck squamous cell carcinoma (HNSCC), NSCLC 
and breast cancer [104-107]. Additionally, various studies reported that EGFR activity up-
regulates HIF-1α also under normoxic conditions [104, 107-110], however, there are 
controversial data aiming to explain as how this event is mediated. On one hand, few studies 
indicate that EGF increases both HIF-1α mRNA and protein levels [111]. On the other hand, 
different studies report that EGFR signaling leads to increased protein translation without 
obvious changes in the mRNA level [112]. Thus, the involvement of this RTK in the 
regulation of HIF-1α seems to be cell-type and cancer-type specific. Similar to other RTKs, 
EGFR activation triggers multiple signal transduction pathways, including the 
phosphatidylinositol 3-kinase (PI3K)/AKT pathway [113] and the RAS/RAF/mitogen-
activated protein kinase (MAPK) pathway [114]. Besides oxygen, ROS and particular Krebs 
cycle metabolites such as fumarate and succinate [115] have also been demonstrated to 
regulate prolyl-hydroxylase activity-mediating HIF-1α stabilization under normoxic 
conditions [107, 116]. H2O2 has been shown to induce EGF-stimulated activation of 
PI3K/AKT signaling in ovarian cancer cells. Increasing evidence shows that H2O2 production 
mediates, at least in part, EGF-induced HIF-1α expression in this cancer type [111]. Indeed, it 
has been frequently reported that PI3K/AKT signaling is involved in induced HIF-1α protein 
expression [104, 105, 117]. A more limited number of studies has examined the impact of 
MAPK signaling on HIF-1α expression. Some reports suggest that inhibition of the MAPK 
pathway does not alter EGFR-induced expression of HIF-1α [112], whereas others reported 
that inhibition of MAPK reduces basal HIF-1α activity through potential phosphorylation 
events [107]. 
 
Apart of EGFR, HER2 plays also an important role in the regulation of HIF-1α. Enhanced 
activity of HER2 occurs in approximately one third of breast tumors and correlates with 
higher tumor grade, resistances to treatment and decreased rates of patient survival [118, 119]. 
HER2 undergoes heterodimerization with the ErbB family members HER3 and HER4, which 
bind heregulin among a subset of stroma-derived growth factors [120]. HER2 overexpression 
or heregulin stimulation have been shown to induce VEGF mRNA and protein expression 
[121, 122]. The use of a specific neutralizing monoclonal antibody against HER2 (4D5) in the 
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treatment of breast cancer cells results in a dose-dependent inhibition of VEGF expression 
[123]. It has been demonstrated that HER2 signaling in normoxic cells promotes 
transcriptional activation of the VEGF gene via HIF-1α and that this transcriptional activity is 
dependent on PI3K/AKT/mTOR signaling [110]. While hypoxia increases HIF-1α protein 
stability and specific transcriptional activity [124], heregulin/HER2 signaling induces 
synthesis of HIF-1α protein, such that a combination of hypoxia and HER2 overexpression 
synergistically increases HIF-1α target genes expression [110]. Normoxic expression of HIF-
1α was reported to mediate HER2 effects on resistance to aromatase inhibitors in breast 
cancer cells [125]. Aromatase inhibitors reduce circulating levels of estrogen and are 
clinically used to treat breast cancer [126]. Resistance to these agents arises following a 
switch from dependence on estrogen receptor signaling to dependence on HER2 signaling 
[127]. HIF-1α orchestrates the activation of target genes involved in processes that promote 
resistance to aromatase inhibitors. In particular, breast cancer resistant protein (BCRP), a HIF-
1α target gene, was reported to play a role in resistance to these agents and in maintenance of 
stem cell characteristics in breast cancer. Hence, inhibition of HIF-1α expression and activity 
has been suggested to extend tumor cells sensitivity to aromatase inhibitors and averting 
recurrence and metastasis [125]. 
 
In contrast to the other ErbB family members, HER4 has been suggested to positively impact 
HIF-1α signaling via a substantially different mechanism. In mammary carcinoma cells, 
HER4 activated by binding of neuregulin-1 was shown to promote accumulation of HIF-1α in 
normoxia, while HER4 signaling resulted in a further increase of HIF-1α protein under 
hypoxic conditions [128]. This corresponding accumulation was shown to result from 
promotion of HIF-1α protein stability in a VHL- and prolyl-hydroxylase-independent manner 
[128]. Proteasomal degradation of HIF-1α was reported to take place by interaction with the 
receptor for activated protein kinase C/RACK1 in an oxygen-independent way [129]. Thus, 
when HER4 is activated, a soluble HER4 intracellular domain is proteolytically released and 
it translocates to the nucleus, where it can directly interact with nuclear HIF-1α, leading to 
suppression of RACK1-dependent proteasomal degradation of HIF-1α [128]. Notably, and in 
support of the role of HER4 in HIF-1α regulation, HIF-1α expression levels in vivo were 
found to be higher in mammary glands of wild-type mice compared to glands of mice in 
which HER4 was ablated [128]. Moreover, HER4 expression was reported to correlate with 
the expression of HIF-1α-regulated genes in a number of human normal and cancer tissue 
samples [128]. 
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3.2.VEGFR 
 
VEGFR signaling has been shown to affect HIF proteins expression and phosphorylation in 
various cell types. Recent studies using neuroblastoma cells indicated that VEGF-induced 
activation of VEGFR-1 leads to increase of both HIF-1α and HIF-2α protein levels [130]. In 
clinical neuroblastoma specimens, HIF-2α protein levels positively correlate with VEGF 
expression and poor patient outcome [131]. Additionally, HIF-1α phosphorylation was shown 
to decrease following inhibition of VEGF/VEGFR-1 autocrine signaling. In this loop, 
VEGFR-1 signaling activates ERK1/2 in new arisen hypoxia. ERK1/2 in turn activates HIF-
1α which up-regulates VEGF and VEGFR-1, leading to further stimulation of ERK1/2. 
VEGFR-1-expressing neuroblastoma cells show hypoxia-mediated resistance to several 
chemotherapeutic agents, including etoposide, doxorubicin, melphalan and cyclophosphamide 
[132]. VEGFR-1 activity was associated with increase of bcl-2, a significant antiapoptotic 
protein, and FGF, a strong angiogenic factor. Hence, such an autocrine VEGF/VEGFR-1- HIF 
loop is likely to contribute to cell survival, drug resistance and angiogenesis during hypoxia 
[132]. 
 
In a similar fashion, in endothelial cells, an interaction between a hypoxia-driven 
VEGF/VEGFR-2 autocrine loop and HIF-1α has also been demonstrated [133]. VEGFR-2 has 
been defined as the dominant signaling receptor in endothelial cells. In contrast, VEGFR-1 
has weak tyrosine kinase activity but a 10-fold higher binding affinity for VEGF. This led to a 
suggestion that VEGFR-1 sequesters VEGF from signaling through VEGFR-2 and thus acts 
as a decoy receptor [134]. However, recent studies in several tumor cells indicate that 
VEGF/VEGFR-1 possesses autocrine survival activity as well [135-137]. 
 
 
3.3. MET 
 
An additional mechanism by which HIF-1α confers oncogenic activity to EGFR is by an 
EGFR-related activation of MET expression. EGFR-activating mutations have been found to 
associate with elevated levels of MET in both NSCLC transgenic murine models and clinical 
samples [138]. Using NSCLC cell lines, Xu et al have shown that the HIF-1α/MET axis plays 
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an important role in regulating invasiveness induced not only by hypoxia but also by EGFR 
signaling. As mentioned in section 1.1., hypoxia is a regulator of HGF, presumably through 
HIF-1α activity [55]. In this respect, Xu et al suggested that EGFR-activating mutations could 
promote production of HGF through HIF-1α and thus EGFR/HIF-1α activation may not only 
regulate MET levels, but also have an impact on MET signal transduction [138]. 
 
In addition, HGF-induced MET activity in hepatoma cells was reported to increase HIF-1α 
mRNA and protein levels as well as activation of HIF-1α DNA-binding and target genes 
expression [139]. Blockade of the PI3K pathway was shown to abrogate the HIF-1α DNA-
binding activity, but inhibition of the MAPK pathway in this respect had no effect. Similarly 
to what has been reported concerning the EGFR, it is likely that ROS produced during HGF- 
triggered signaling play a critical role [139]. ROS are recognized as stress-associated stimuli, 
which can activate the NF-κB transcription factor. Indeed, in different cancer cell lines, it has 
been reported that transduction pathways triggered by the HGF/MET binding lead to 
activation of NF-κB, which is able to regulate expression of HIF-1α [140]. Based on 
luciferase reporter assays, the regulation by NF-κB seems to be mediated by binding to the 
5’UTR region of the HIF-1α mRNA [140]. 
 
Abrogating the HGF/MET signaling axis using decorin, a small leucine-rich proteoglycan, 
was reported to reduce HIF-1α and VEGF-A expression in breast carcinoma cells, thereby 
repressing VEGF-A-mediated angiogenesis under normoxia. This effect has been attributed to 
MET inhibition as suppression of MET expression using siRNA evoked a similar reduction of 
VEGF-A protein levels [141]. However, decorin is known to induce down-regulation of 
multiple RTKs apart of the MET receptor, including EGFR [142-144] and other ErbB family 
members [145]. It antagonizes these RTKs by receptor internalization via caveolar-mediated 
endocytosis [146] confirming once again that EGFR as well as MET signaling both seem to 
have a strong impact on the HIF-1α transcription factor activity.  
 
 
3.4. IGFR1 and IR 
 
IGF1R signaling, similarly to HER2 activation, was shown to mediate resistance to aromatase 
inhibitors [127]. In glioblastoma cells, IGF1R activation by stimulation either with IGF1 or 
IGF2 was shown to give rise to HIF-1α protein expression, HIF-1α DNA-binding activity and 
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transcriptional activation of its downstream target genes [147]. In colon cancer cells, the 
increased HIF-1α expression following IGF1 treatment was shown to be triggered by 
stimulation of HIF-1α protein synthesis [40]. As previously mentioned, IGF2 is among the 
target genes that are transactivated by HIF-1α, thereby providing a link in an autocrine self-
amplifying loop [147]. In contrast to heregulin-stimulated breast cancer cells, enhanced HIF-
1α protein synthesis in colon cancer cells is dependent rather on STAT3 than on mTOR. For 
IGF1R signaling, PI3K/AKT/mTOR activation requires intracellular recruitment of insulin 
receptor substrates (IRS) 1 and 2 to the activated receptor [148]. As mTOR is known to 
downregulate IRS1/2 [149], activation of this pathway would have a self-inhibitory effect on 
HIF-1α synthesis. In many tumor types, the JAK/STAT pathway has been defined as 
important mediator of IGF-dependent signaling [150]. STAT3 can be recruited by IGF1R 
independently of IRS1/2 and subsequently modulate expression of AKT [151]. Particularly in 
hypoxic tumors bearing autocrine regulation of the IGF-HIF-1α axis, pharmacological 
inhibition of IGFR1 or STAT3 may provide a significant therapeutic benefit. Indeed, HIF-1α 
synthesis was shown to be abrogated in glioblastoma cells following exposure to the selective 
IGF1R inhibitor NVP-AEW541 [147]. 
 
IGF1/2 have many signaling effectors and cellular responses that are shared with insulin and 
the insulin receptor (IR) [152]. Insulin is a central regulator of metabolic pathways associated 
with energy storage and utilization [153]. Both hypoxia and insulin increase the level of 
glucose transporters and glycolytic enzymes [154, 155], contributing to increased glycolysis 
[153]. Emerging evidence suggests that binding of insulin to IR induces HIF-1α protein 
translation through activation of the PI3K/AKT/mTOR pathway in retinal epithelial cells 
[156]. mTOR seems to be involved in the insulin action on HIF-1α regulation only partly, as 
inhibition of mTOR does not completely abolish HIF-1α expression. This finding suggests 
that both an AKT-dependent/mTOR-independent and an AKT/mTOR-dependent pathway 
may be involved in insulin-induced HIF-1α-translation [156]. HIF-1α expressed through 
insulin stimulation increasingly activates transcription of VEGF [156]. In fact, intraocular 
VEGF levels have been observed to be increased in diabetic patients suffering from 
proliferative retinopathy due to hyperinsulinemia induced by insulin treatment [157]. 
 
 
3.5. PDGFR, FGFR and RET 
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As mentioned in section 1.1., PDGF can increase transcription and secretion of VEGF by 
PDGFR-expressing endothelial cells. Elevated PDGFR levels have been commonly observed 
in neovascular endothelial cells during tumorigenesis but the downstream molecular 
mechanisms by which PDGF transduces its signals via PDGFR to mediate VEGF secretion 
were not known [158]. In a recent study using vascular smooth muscle cells (VSMS), Richard 
et al reported that PDGF can increase HIF-1α protein to levels that are more elevated than in 
hypoxia, which may play a major role in VEGF production [159]. On the other hand, PDGF 
leads only to a small or no increase of HIF-1α levels in fibroblasts and in endothelial cells, 
respectively [159], rendering this effect to be cell-specific. As for other RTK pathways, it was 
reported that the increase of HIF-1α protein level is mediated through the production of ROS 
[159]. This mechanism emphasizes the importance of up-regulation of PDGF or its receptors 
in regulating of the angiogenic switch in early stages of tumor development, in contrast to 
hypoxia, being a stimulus for neovascularization in an already established tumor [158]. 
 
Other major angiogenic inducers, the FGFRs, were also found to be involved in the regulation 
of the hypoxic pathway [160]. Cord formation of human umbilical vein endothelial cells 
(HUVECs) was shown to depend on HIF-1α activity and on the induction of FGFRs. 
Knockdown of either HIF-1α or FGF2 indicated that FGF2 and HIF-1α reciprocally regulate 
their expression [161]. These findings suggest the existence of a crosstalk between HIF-1α 
and FGF2 that mediates an autocrine pathway in hypoxia [161]. 
In glioblastoma, FGF2 seems to play an important role in the response to ionizing radiation. 
Preclinical treatment with SSR12819E, the first-in-class compound able to inhibit FGF2 
binding to FGFR-1 [162] was reported to decrease glioblastoma cells radioresistance both in 
vitro and in vivo [163]. The radiosensitizing effect of SSR12819E might be a consequence of 
FGFR-1 endocytosis and subsequent degradation. At the same time, inhibition of the small 
GTPase RHOB, usually induced by FGF2 stimulation, occurs [160]. Abrogating RHOB 
activity enhances proteasome-dependent degradation of HIF-1α [163], showing that 
regulation of HIF-1α by FGFR-1 could be involved in resistance to radiation therapy. 
 
The increased resistance of glioblastoma cells to ionizing radiation is potentially mediated 
through transactivation of specific target genes by HIF-1α. One direct target gene whose 
expression significantly correlates in many tumor types with poor prognosis and resistance to 
chemotherapy in general is carbonic anhydrase IX (CAIX) [164], an enzyme which promotes 
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conversion of carbon dioxide to bicarbonate ions and protons. CAIX plays an important role 
in pH regulation, a crucial step for survival of tumor cells in hypoxia and acidosis [165]. Its 
expression has been found almost exclusively in tumors and it is considered as one of the 
main intrinsic markers of tumor hypoxia [164, 166]. Recently, CAIX expression was reported 
to correlate with overexpression of the RET RTK in medullary thyroid carcinoma. 
Overexpression of RET, which mimics ligand-independent activation often occurring in 
advanced medullary thyroid carcinomas, increases CAIX promoter activity induced by HIF-
1α in a cellular model [167]. It is suggested that both PI3K and MAPK pathways can mediate 
this phenomenon [167]. The crosstalk between RET and HIF-1α has been described also in 
neuroblastoma cells, where activation of RET induced by its ligand GDNF increases HIF-1α 
protein levels [130]. In turn, expression of GDNF was reported to be increased in hypoxic rat 
astrocytes [168]. This ligand-dependent stimulation may create a positive feedback loop in the 
hypoxic pathway. 
 
4. Tentative treatment perspectives on the crossroad of HIF-RTK signaling 
 
There are numerous reviews focusing on targeting HIF-1 as well as RTK systems in cancer. 
In this section, we are specifically aiming at discussing strategies, which might be relevant for 
the crosstalk between hypoxia and RTKs activated pathways. 
As signaling by various RTKs was shown to elevate HIF-1α as well as HIF-2α protein levels 
and similarly, the activity of these two transcription factors induces signaling by several 
RTKs, combining HIF inhibitors with RTK targeting agents may proof as an effective anti-
cancer treatment. Such combined modalities may allow lower doses of each individual drug, 
thereby reducing the probability of off-targeting toxic effects and also reduce the likelihood of 
selecting for drug resistant cancer cells. Many of the currently available molecules targeting 
the HIF system show preferential activity against HIF-1α, with less or no effect on HIF-2α 
[169]. Interestingly, these agents, such as digoxin, etoposide or YC-1, have been originally 
designed to act on cellular targets distinct than HIF-1α, and HIF-1α  inhibition was observed 
as a secondary effect [169]. Here we will discuss the mechanisms of action of these 
compounds and the impact of their use on the HIF-RTK systems crosstalk. 
Digoxin belongs to a class of cardiac glycosides used to treat congestive heart failure and 
arrhythmias. Cardiac glycosides bind to the α-subunit of the sodium pump (Na+/K+ ATPase) 
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and inhibit its activity [170]. The sodium pump is most abundantly expressed in ion-
transporting epithelia and is responsible for translocating sodium and potassium ions across 
the cell membrane utilizing ATP as the driving force [170]. Studies conducted over the last 
decade suggest that cardiac glycosides may be successful as anti-cancer agents [170, 171]. 
Digoxin and other members of this class were shown to inhibit HIF-1α protein synthesis and 
expression of HIF-1α target genes in several cancer cells [172]. However, the mechanism by 
which these effects are mediated remains unclear. It was suggested that cardiac glycosides 
promote sequestration of HIF-1α mRNA in stress granules [172], which are usually formed 
following exposure of cancer cells to hypoxia and contain mRNAs which are not translated 
until the cells are reoxygenated [173]. 
In general, digoxin was found to increase tumor latency and inhibit tumor xenograft growth in 
mice. As discussed in detail in section 2.1., in mice bearing breast cancer orthografts, digoxin 
was reported to block lymphangiogenesis and lymphatic metastases to a similar extent as 
PDGFRβ inhibition by imatinib [36]. Interestingly, xenografts derived from cells with HIF-1α 
enforced expression were resistant to the anti-tumor effect of digoxin, showing that HIF-1α is 
the critical target of digoxin for cancer therapy [172]. Currently, digoxin is evaluated in a 
phase 2 clinical trial intended for newly diagnosed operable breast cancer [174]. 
Another class of potential HIF-1α-targeting agents is represented by topoisomerase (Top) 
inhibitors. Top inhibitors were originally designed and are being primarily used to induce 
cellular DNA damage [175]. Later on, both Top I and II inhibitors were shown to modulate 
HIF-1α synthesis. Topotecan, a representative member of Top I inhibitors [176, 177], has 
been the first agent from this class of inhibitors to be tested in humans for the purpose of 
inhibiting HIF-1α synthesis [178]. Currently, topotecan is approved as HIF antagonist for the 
treatment of metastatic ovarian cancer, small cell lung cancer and cervical cancer [174]. In 
addition, the Top II inhibitor etoposide was reported to circumvent EGFR up-regulation in 
HIF-2α-overexpressing cancer cells (discussed in 2.3.) [79, 80], being eventually one of the 
few agents capable to target not only HIF-1α, but also HIF-2α. In NSCLC cells, topotecan and 
etoposide were both shown to inhibit the accumulation of hypoxia-induced HIF-1α protein 
through the PI3K-AKT pathway and proteasomal degradation [175]. This inhibitory effect 
seems to be dependent on the expression of Tops, as silencing of these proteins abrogates the 
inhibition of HIF-1α accumulation [175] but the exact mechanism of how expression of Tops 
affects HIF-1α metabolism has not been elucidated yet [175].  
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YC-1 (3-[5’hydroxymethyl-2’-furyl]-1-benzylindazole), a nitric oxide-independent activator 
of soluble guanylyl cyclase, was originally developed as a therapeutic agent for circulation 
disorders. YC-1 inhibits platelet aggregation and vascular contraction by activating soluble 
guanylyl cyclase [179, 180]. Interestingly, YC-1 was reported to downregulate HIF-1α and to 
suppress IGF1R signaling, thus overcoming gefitinib resistance in NSCLC cells expressing 
activating EGFR mutations (2.3.) [92]. Moreover, YC-1 was shown to block HIF-1α 
expression at the posttranscriptional level and consequently to inhibit transcription factor 
activity of HIF-1α in vitro [181]. It was suggested that YC-1 prevents HIF-1α translation by 
inhibiting PI3K-AKT and NF-κB signaling during hypoxia [182]. In fact, NF-κB function can 
be stimulated by phosphorylation through AKT [183] and, as aforementioned, activated NF-
κB was found to upregulate HIF-1α expression [140]. Tumors from YC-1-treated mice are 
generally significantly smaller, express lower levels of HIF-1α and are less vascularized, 
regardless of tumor type [181]. However, as potential use of YC-1 is likely to result in 
increased bleeding time and hypotension at dosages relevant for cancer chemotherapy, this 
drug has not been tested in clinical trials to date [174]. Potential side effects of YC-1 have to 
be carefully evaluated before this compound or its eventual analogues could be developed as 
new anticancer agents [181]. 
In addition to these pharmacological agents, HIF-1α levels were reported to be affected by 
therapeutic interventions that perturb signaling cascades that are activated by RTKs. This 
category of compounds include primarily mTOR inhibitors as temsirolimus (CCI-779) and 
everolimus (RAD001), which are clinically approved drugs [174]. Upon activation of the 
PI3K/AKT pathway, mTOR phosphorylates eIF4F-binding proteins that serve as negative 
regulators of the eIF4F translation initiation complex, resulting in its release from inhibition 
with concomitant translation of proteins involved in cell cycle progression, in addition to 
increased translation of HIF [184, 185]. Among the first preclinical studies that reported 
observations along this line is a 2006 work by Del Bufalo et al who showed that in BT474, a 
human breast cancer line that harbors HER2 amplification, temsirolimus inhibited VEGF 
production under both normoxic and hypoxic conditions through inhibition of HIF-1α 
expression and transcriptional activation [186]. In a subsequent study, Wangpaichitr et al 
reported that HIF-1α down-regulation by temsirolimus coincided with increased toxicity 
towards the glycolysis inhibitor 2-deoxy-d-glucose in lung cancer cells [187]. Likewise, 
treatment with everolimus was reported to repress expression of HIF-1α and its transcriptional 
target VEGF in ovarian clear cell adenocarcinoma models [188]. Furthermore, it was shown 
that the use of everolimus reversed a prostatic intraepithelial neoplasia phenotype in mice by 
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decreasing not only HIF-1α protein, but also mRNA level as well as expression of HIF-1α 
target genes encoding enzymes essential for glycolysis [189]. It is important however to 
emphasize that these reported observations so far have been detected in preclinical models. 
The impact level of mTOR inhibitors on HIF-1α orchestrated metabolism in patients needs 
yet to be determined. 
In addition to HIF-1α inhibition, gene products regulated by HIF-1α that activate RTKs 
signaling can be considered as targets. In this respect, the use of the approved monoclonal 
antibody bevacizumab which blocks VEGF-A [190] has been tested in combination with 
bortezomib in a phase 1 clinical trial [190]. Bortezomib is a proteasomal inhibitor, which, as 
other agents belonging to this class, increases overall HIF-1α levels, but inhibits HIF function 
by targeting its C-terminal activation domain (CAD) [191]. According to the aforementioned 
clinical trial, bevacizumab and bortezomib are well-tolerated and have achieved an inhibition 
of angiogenic activity in patients with previously treated advanced malignancies [190]. 
In summary, as emerging evidence suggests that inhibition of a single RTK overexpressed in 
hypoxia may fail due to the involvement of HIF-1α-dependent induction of effectors 
implicated in tumor progression, combination treatment with HIF inhibitors emerges as an 
important potential strategy for improving the efficacy of RTK targeting agents, particularly 
in cases when hypoxic regions within tumors are evident. 
 
5. Conclusions 
 
Solid tumors develop hypoxic regions primarily due to aberrant neovascularization with 
consequent poor blood supply. Lesions with deprived oxygenation may manifest particular 
aggressive phenotypes due to series of cellular adaptations that sustain and eventually foster 
tumor local invasion and systemic dissemination. A major common feature of hypoxic tumors 
is the activation of the HIF system, leading essentially to upregulation of a battery of genes 
encoding for proteins that support cellular survival in low-oxygen conditions. 
Dysregulation of RTK signaling is an abundant feature of a wide range of cancers and is 
generally associated with increased cell proliferation, motility and resistance to cell death 
signals.  As previously discussed, under low oxygen tension, signaling by various RTK 
systems is considerably amplified. This hypoxia-stimulated increase in RTK signaling is 
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mediated through several distinct mechanisms including transcriptional activation, enhanced 
mRNA stability, which is associated with increased translation of some RTKs or of their 
ligands, delayed RTK endocytosis as well as downregulation of proteins and miRNAs, which 
negatively regulate RTK expression and signaling. Likewise, signaling by various RTK 
systems was found to activate the HIF system, by inducing transcription or translation of HIF-
1α/HIF-2α, by increasing the protein stability or by enhancing the DNA-binding and 
transactivation ability of HIF transcription factors. 
In summary, although the current knowledge on RTKs signaling under hypoxic conditions 
and the impact of RTKs signaling on HIF-associated pathways is continuously expanding, the 
detailed molecular mechanisms underlying many of the observations described within this 
review remain largely unknown. However, this emerging intricate molecular crosstalk 
between RTK systems and hypoxic pathways, each correlated with bad prognosis and 
increased patient mortality, strongly supports the rationale of combining HIF inhibitors with 
RTK targeting for the treatment of various solid cancers. This strategy could particularly turn 
out to be effective in suppressing aberrant RTKs signaling axes, which are dependent on 
activation via the HIF transcriptional machinery. 
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Table 1: Mechanisms of RTK activation through hypoxia in experimental tumor cellular 
models 
Cell type RTK / ligands mechanism 
SiHa cervix squamous cell 
carcinoma cells, HepG2 
hepatocellular carcinoma 
cells, A549 lung carcinoma 
cells, MLP-29 mouse liver 
progenitor cells, PK8 
pancreatic cancer cells 
MET Transcriptional activation by HIF-1α [49, 55] 
SN12L1 clear cell renal cell 
carcinoma (ccRCC) cells 
MET AXL signalling mediated lateral activation by 
SRC 
[62] 
RCC4 ccRCC cells, 786-0 
ccRCC cells, HepG2 
hepatocellular carcinoma 
cells, Hep3B hepatocellular 
carcinoma cells 
AXL Transcriptional activation by HIF-1α and HIF-2α 
[62]
 
HLEC lens epithelial cells, 
PC3 and Du-145 prostate 
cancer cells 
AXL Inhibition of GAS6-mediated AXL 
downregulation
 [65, 66]
 
MCF7, ZR-75, MDA-MB-
231 and MDA-MB-468 
breast cancer cells 
RON Transcriptional activation by HIF-1α [69] 
Numerous cancer types VEGF-A Transcriptional activation by HIF-1α [13, 18, 23] 
Rat pulmonary 
microvascular smooth 
muscle cells 
VEGF-D Transcriptional activation by HIF-1α [28] 
Bovine retinal endothelial 
cells, bovine retinal pericytes 
VEGF Enhanced mRNA due to increased protein kinase 
A (PKA) activity 
[29, 30]
 
U87 glioblastoma cells, 293 
human embryonic kidney 
cells 
VEGF Expression induced by increased SRC activity 
[31]
 
Rat pheochromocytoma 
cells, rat heart myocytes, rat 
glioma cells 
VEGF mRNA stabilization 
[32-34]
 
MDA-MB-231 and MDA-
MB-435 breast cancer cells, 
U87, U251 and A172 
glioblastoma cells 
PDGF-B Transcriptional activation by HIF-1α [36, 37] 
HEPG2 HCC cells, mouse IGF2 Increased expression indirectly mediated by HIF-
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embryonic fibroblast and 
embryonic stem cells 
1α [41-43] 
786-0 ccRCC cells TGFα Production induced by increased HIF in VHL null 
cells 
[45]
 
Astrocytes isolated from 
stroke-prone spontaneously 
hypertensive rats 
GDNF Increased expression potentially mediated by 
HIF-1α [130, 168] 
Non-small cell lung cancer 
(NSCLC), RCC, breast 
cancer, prostate cancer, 
glioblastoma cells 
EGFR mRNA translation through activated HIF-2α [76, 
79]
 
786-0 ccRCC cells EGFR Delayed receptor endocytosis 
[81]
 
786-O ccRCC EGFR Ligand-independent activation through elevated 
expression of CAV1 
[86]
 
T-47D and MDA-MB-468 
breast cancer cells, HEK293 
human embryonic kidney 
cells 
HER4 Delayed receptor endocytosis 
[82]
 
Caco-2 colorectal 
adenocarcinoma cells 
HER2/HER3 Enhanced signalling through downregulation of 
Necl-2 
[72]
 
PC9 and HCC827 NSCLC 
cells 
IGF1R Enhanced signalling in Gefitinib-resistant CSC 
[92]
 
RT4, RT112 and T24 
bladder cancer cell lines 
FGFR3 Increased mRNA levels through suppression of 
miR-100 
[98]
 
 
Figure legends 
Figure 1: Hypoxia-induced activation of RTK systems (See text for details) 
Figure 2: Signaling by RTK activates the HIF pathway (See text for details) 
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